Dr. Rath Health Foundation

Dr. Rath Health Foundation

Responsibility for a healthy world Dr. Rath Research Institute 100+ Studies Published In PubMed

Outlaw the "Business with Disease": The Chemnitz Program

Criminal Reaction of the Pharma-Cartel

To implement these unethical plans, the Pharma-Cartel maintains a legion of hired lobbyists. In Washington, D.C. alone, over 1,000 lobbyists work for the Pharma-Cartel, two lobbyists for each member of Congress. The figures are comparable for Germany. The mission of each lobbyist is to influence public opinion and legislation in the most important industrialized countries. All of this in the interest of the pharmaceutical cartel; day in, day out. Many opinion leaders in science and medicine are also affected by the influence of the pharmaceutical cartel.

The U.S. Academy of Science initially promised to publish the scientific breakthrough towards the “Solution to the Puzzle of Cardiovascular Disease.” Due to the influence of the Pharma-Cartel within the Academy of Science, publication was cancelled only weeks later. The following argument was given: “As there is no puzzle in cardiovascular disease, there can be no solution either.” That this unsolved puzzle continues to take every second human life in the U.S. and beyond had apparently escaped the attention of these gentlemen. We did not hesitate to publish our important publication in a Canadian Journal of Nutritional Medicine.

We left no other stone unturned to guarantee the rapid dissemination of this lifesaving information. We presented this new therapy about cardiovascular disease to more than a dozen pharmaceutical companies in order to improve human health on a worldwide scale, with the help of a strong partner. All pharmaceutical companies in 1991 said, “No” with the exception of one, Hoffmann-LaRoche, the world’s largest manufacturer of vitamin C. In November, 1991, I introduced my work to the heads of research at the headquarters of the Roche Company in Basel, Switzerland. Roche immediately understood the worldwide importance of this medical breakthrough. Nevertheless, shortly thereafter they expressed that they were not interested in any collaboration. Hoffmann-LaRoche’s official reason for declining was that they do not want to finance a medical breakthrough for its competition! What a remarkable excuse!

Five years later the world learned what had really happened: in expectation of a worldwide increased demand for vitamin C, lysine and other natural substances mentioned in my work, the Roche Corporation used this information for an artificial increase in the price of the raw materials for these natural substances. In addition, together with the German Bayer Corporation and the U.S. firm Archer-Daniels-Midland, Roche formed a cartel for criminal price fixing of the natural substances mentioned in our work. Isn't it remarkable that these pharmaceutical companies did not want to spend a single dime to spread the information about the eradication of heart disease? At the same time, they made sure that they cannibalized this process by selling the raw material at prices that have almost doubled the retail price for these vitamin products.

On January 30th, 1997, the New York Times reported that U.S. federal prosecutors had uncovered the most comprehensive case of criminal price fixing in the history of the United States. According to U.S. prosecutors quoted in the New York Times, the dimension of this fraud was so vast that “literally hundreds of products and almost every consumer” was affected. A key witness stated that the criminal acts were designed at the highest level of the Roche, Bayer, and other corporations, and that the corporate masterminds were “the masters” whereas the subordinates who had to do the dirty work were called the “sherpas.” All three companies were found guilty.

From here on everyone can describe Roche, Bayer, and the other pharmaceutical companies publicly as what they are: criminals, who have no scruples to profit at the expense of the health and lives of millions of people.

Continue...
Back to overview...